Metabolic syndrome - From the neurotrophic hypothesis to a theory

Medical Hypotheses

Volumn 81, Issue 4, 2013, Pages 627-634

  Hristova, M G ^a  

^a MEDICAL UNIVERSITY OF VARNA   (Bulgaria)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ADIPOCYTOKINE; ADIPONECTIN; BRAIN DERIVED NEUROTROPHIC FACTOR; C REACTIVE PROTEIN; GLUCOCORTICOID; GLUCOSE; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 6; LEPTIN; NEUROPEPTIDE Y; NEUROTROPHIN; PROTEIN P75; PROTEIN TYROSINE KINASE A; TESTOSTERONE; TRIACYLGLYCEROL; TRYPTOPHAN; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ARTERIAL PRESSURE; ARTICLE; AUTONOMIC NERVOUS SYSTEM; CHRONIC STRESS; CIRCADIAN RHYTHM; CORONARY ARTERY ATHEROSCLEROSIS; CYTOKINE PRODUCTION; DEPRESSION; DIABETIC NEUROPATHY; DISEASE COURSE; DISTRESS SYNDROME; ENERGY BALANCE; GLUCOSE METABOLISM; HEART PROTECTION; HUMAN; HYPERCORTISOLISM; HYPERINSULINEMIA; HYPERPROLACTINEMIA; HYPOPHYSIS ADRENAL SYSTEM; HYPOPITUITARISM; HYPOTHALAMUS; HYPOTHYROIDISM; INFLAMMATION; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPID METABOLISM; MACROPHAGE ACTIVATION; MAST CELL; MENTAL STRESS; METABOLIC SYNDROME X; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PATHOGENESIS; SLEEP DISORDER; WAIST CIRCUMFERENCE;

ADIPOKINES; AFFECTIVE SYMPTOMS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CYTOKINES; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INFLAMMATION; LEPTIN; METABOLIC SYNDROME X; MODELS, BIOLOGICAL; NERVE GROWTH FACTOR; NERVE GROWTH FACTORS; NEUROTRANSMITTER AGENTS; PITUITARY-ADRENAL SYSTEM;

EID: 84883769675     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.07.018     Document Type: Article

References (186)

1. Hristova M., Aloe L. Metabolic syndrome - neurotrophic hypothesis. Med Hypotheses 2006, 66(3):545-549.
2. Hristova M. Metabolic syndrome and neurotrophins: effects of metformin and non-steroidal anti-inflammatory drug treatment. Eur J Med 2011, 43:141-145.
3. Gustafson B. Adipose tissue, inflammation and atherosclerosis. J Atheroscler Thromb 2010, 17:332-441.
4. Chaldakov G., Aloe L., Hristova M., et al. NGF-OME: its metabotrophic expression homage to Rita Levi-Montalcini. Biomed Rev 2010, 21:25-29.
5. Schug T.T., Xu Q., Gao H., et al. Myeloid deletion of SIRT1 induces inflammatory signaling response to environmental stress. Mol Cell Biol 2010, 30:4712-4721.
6. Maes M., Twisk F.N. Why myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) may kill you: disorders in the inflammatory and oxidative and nitrosative stress (IO&NS) pathways may explain cardiovascular disorders in ME/CFS. Neuro Endocrinol Lett 2009, 30:677-693.
7. Mauras N., Delgiorno C., Kollman C., et al. Obesity without established comorbidities of the metabolic syndrome is associated with a proinflammatory and prothrombotic state, even before the onset of puberty in children. J Clin Endocrinol Metab 2010, 95:1060-1068.
8. Hector J., Schwarzloh B., Goehring J., et al. TNF-alpha alters visfatin and adiponectin levels in human fat. Horm Metab Res 2007, 39:250-255.
9. Lubitskaia N.S., Antoniuk M.V., Veremchuk L.V., Khodosova K.K. Role of tumor necrosis factor in the development of metabolic syndrome. Ter Arkh 2009, 81(11):59-63. (in Russian).
10. Bastard J.P., Maachi M., Lagathu C., et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006, 17:4-12.
11. Fenkci S., Rota S., Sabir N., Sermez Y., Guclu A., Akdag B. Relationship of serum interleukin-6 and tumor necrosis factor alpha levels with abdominal fat distribution evaluated by ultrasonography in overweight or obese postmenopausal women. J Investig Med 2006, 54:455-460.
12. Trøseid M., Lappegård K.T., Mollnes T.E., Arnesen H., Seljeflot I. The effect of exercise on serum levels of interleukin-18 and components of the metabolic syndrome. Metab Syndr Relat Disord 2009, 7:579-584.
13. Elks C.M., Francis J. Central adiposity, systemic inflammation, and the metabolic syndrome. Curr Hypertens Rep 2010, 12:99-104.
14. Siklar Z., Berberoǧlu M., Uysal Z., et al. Cytokines as common components of two different disorders: metabolic syndrome and hemophagocytic lymphohystiositosis. Exp Clin Endocrinol Diabetes 2009, 117:57-59.
15. Krueger J. The role of cytokines in sleep regulation. Curr Pharm Des 2008, 14:3408-3416.
16. Frisbee J.C., Samora J.B., Peterson J., Bryner R. Exercise training blunts microvascular rarefaction in the metabolic syndrome. Am J Physiol Heart Circ Physiol 2006, 291:H2483-H2492.
17. Pravenec M., Kajiya T., Zídek V., et al. Effects of human C-reactive protein on pathogenesis of features of the metabolic syndrome. Hypertension 2011, 57:731-737.
18. Kressel G., Trunz B., Bub A., et al. Systemic and vascular markers of inflammation in relation to metabolic syndrome and insulin resistance in adults with elevated atherosclerosis risk. Atherosclerosis 2009, 202:263-271.
19. Maes M. Inflammatory and oxidative and nitrosative stress pathway underpinning chronic fatigue, somatization and psychosomatic symptoms. Curr Opin Psychiatry 2009, 22:75-83.
20. Hakariya Y., Kuratsune H. Chronic fatigue syndrome: biochemical examination of blood. Nippon Rinsho 2007, 65:1071-1076. (in Japanese).
21. Maloney E.M., Boneva R.S., Lin J.M., Reeves W.C. Chronic fatigue syndrome is associated with metabolic syndrome: results from a case-control study in Georgia. Metabolism 2010, 59:1351-1357.
22. Kuratsune H. Overview of chronic fatigue syndrome focusing on prevalence and diagnostic criteria. Nippon Rinsho 2007, 65:983-990. (Japanese).
23. Yamamoto K., Okazaki A., Ohmori S. The relationship between psychosocial stress, age, BMI, CRP, lifestyle, and the metabolic syndrome in apparently healthy subjects. J Physiol Anthropol 2011, 30:15-22.
24. Seematter G., Binnert C., Tappy L. Stress and metabolism. Metab Syndr Relat Disord 2005, 3:8-13.
25. Charmandari E., Kino T., Souvatzoglou E., Chrousos G.P. Pediatric stress: hormonal mediators and human development. Horm Res 2003, 59:161-179.
26. Saruta J., Lee T., Shirasu M., et al. Chronic stress affects the expression of brain-derived neurotrophic factor in rat salivary glands. Stress 2010, 13:53-60.
27. Saruta J., Sato S., Tsukinoki K. The role of neurotrop7hins related to stress in saliva and salivary glands. Histol Histopathol 2010, 25:1317-1330.
28. Saruta J., Kondo Y., Sato C., Shiiki N., Tsukinoki K., Sato S. Salivary glands as the source of plasma brain-derived neurotrophic factor in stressed rats engaged in biting behaviour. Stress 2010, 13:238-247.
29. Tsukinoki K., Saruta J., Muto N., et al. Submandibular glands contribute to increases in plasma BDNF levels. J Dent Res 2007, 86:260-264.
30. Cirulli F., Alleva E. The NGF saga: from animal models of psychosocial stress to stress-related psychopathology. Front Neuroendocrinol 2009, 30:379-395.
31. Sornelli F., Fiore M., Chaldakov G.N., Aloe L. Adipose tissue-derived nerve growth factor and brain-derived neurotrophic factor: results from experimental stress and diabetes. Gen Physiol Biophys 2009, 28:179-183.
32. Fiore M., Chaldakov G., Aloe L. Nerve growth factor as a signaling molecule for nerve cells and also for the neuroendocrine-immune systems. Rev Neurosci 2009, 20:133-145.
33. Berry A., Bindocci E., Alleva E. NGF, brain and behavioral plasticity. Neural Plast 2012, 10.1155/2012/784040.
34. Cabrera-Vasquez S., Navarro-Tableros V., Sanchez-Soto C., Gutierrez-Ospina G., Hiriart M. Remodeling sympathetic innervation in rat pancreatic islets ontogeny. BMC Dev Biol 2009, 9:34-44. 10.1186/1471-213X-9-34.
35. Rosenbaum T., Vidaltamayo R., Sanchez-Soto M.C., Zentello A., Hiriart M. Pancreatic beta cells synthesize and secrete nerve growth factor. Proc Natl Acad Sci USA 1998, 95:7784-7788.
36. Larrieta M.E., Vital P., Mendoza-Rodriguez A., Cerbon M., Hiriart M. Nerve growth factor increases in pancreatic beta cells after streptozotocin-induced damage in rats. Exp Biol Med (Maywood) 2006, 231:396-402.
37. Hiriart-Urdanivia M., Navvaro-Tableros V., Velasco M., et al. Insulin regulation in development and obesity. Advances in obesity-diabetes research at UNAM 2010, 69-79. Manual Moderno, Mexico, D.F. M. Hiriart-Urdanivia, J. Mas-Olivia (Eds.).
38. Abe T., Morgan D.A., Gutterman D.D. Protective role of nerve growth factor against postischemic dysfunction of sympathetic coronary innervation. Circulation 1997, 95:213-220.
39. Hasan W., Jama A., Donohue T., et al. Sympathetic hyperinnervation and inflammatory cell NGF synthesis following myocardial infarction in rats. Brain Res 2006, 1124:142-154.
40. Bullo M., Peeraully M.R., Trayhurn P., Folch J., Salas-Salvado J. Circulating nerve growth factor levels in relation to obesity and the metabolic syndrome in women. Eur J Endocrinol 2007, 157:303-310.
41. Cheng J.T., Tong Y.C. Alterations of nerve-growth factor and P75(NTR) expressions in urinary bladder of fructose-fed obese rats. Neurosci Lett 2008, 441:25-28.
42. Kangavari S., Oh Y.S., Zhou S., et al. Radiofrequency catheter ablation and nerve growth factor concentration in humans. Heart Rhythm 2006, 3:1150-1155.
43. Sposato V., Manni L., Chaldakov G.n., Aloe L. Streptozotocin-induced diabetes is associated with changes in NGF levels in pancreas and brain. Arch Ital Biol 2007, 145:87-97.
44. Geroldi D., Minoretti P., Emanuele E. Brain-derived neurotrophic factor and the metabolic syndrome: more than just a hypothesis. Med Hypotheses 2006, 67:195-196.
45. Golden E., Emiliano A., Maudsley S., et al. Circulating brain-derived neurotrophic factor and indices of metabolic and cardiovascular health: data from the baltimore longitudinal study of aging. PLoS One 2010, 5(4):e10099. 10.1371/journal.pone.0010099.
46. Chaldakov G., Fiore M., Tonchev A., Aloe L. Neuroadipology: a novel component of neuroendocrinology. Cell Biol Int 2010, 34:1051-1053.
47. Manni L., Nikolova V., Vyagova D., Chaldakov G.N., Aloe L. Reduced plasma levels of NGF and BDNF in patients with acute coronary syndromes. Int J Cardiol 2005, 102:169-171.
48. Chaldakov G.N., Fiore M., Hristova M.G., Aloe L. Metabotrophic potential of neurotrophins: implication in obesity and related diseases?. Med Sci Monit 2003, 9:HY19-HY21.
49. Tonra J.R., Ono M., Liu X., et al. BDNF improves blood glucose control and alleviates fasting hyperglycemia in C57BLKS-Lepr(db)/lepr(db) mice. Diabetes 1999, 48:588-594.
50. Wang C., Gordar R.J., Billington C.J., Kotz C.M. Chronic administration of brain-derived neurotrophic factor in the hypothalamic paraventricular nucleus reverses obesity induced by high-fat diet. Am J Physiol Regul Integr Comp Physiol 2010, 298:R1320-R1332.
51. Yamanaka M., Itakura Y., Ono-Kishino M., Tsuchida A., Nakagawa T., Taiji M. Intermittent administration of brain-derived neurotrophic factor (BDNF) ameliorates glucose metabolism and prevents pancreatic exhaustion in diabetic mice. J Biosci Bioeng 2008, 105:395-402.
52. Levinger I., Goodman C., Matthews V., et al. BDNF, metabolic risk factors, and resistance training in middle-aged individuals. Med Sci Sports Exerc 2008, 40:535-541.
53. Suwa M., Kishimoto H., Nofuji Y., et al. Serum brain-derived neurotrophic factor level is increased and associated with obesity in newly diagnosed female patients with type 2 diabetes mellitus. Metabolism 2006, 55:852-857.
54. Chaldakov G.N., Fiore M., Stankulov I.S., et al. NGF, BDNF, leptin, and mast cells in human coronary atherosclerosis and metabolic syndrome. Arch Physiol Biochem 2001, 109:357-360.
55. Chaldakov G.N., Fiore M., Stankulov I.S., et al. Neurotrophin presence in human coronary atherosclerosis and metabolic syndrome: a role for NGF and BDNF in cardiovascular disease?. Prog Brain Res 2004, 146:279-289.
56. Hristova M., Chaushev B., Klissarova A., Kovacheva T. Submandibular glands in the metabolic syndrome. Biomed Rev 2007, 18:65-67.
57. Klisarova A., Chaushev B., Bochev P., Hristova M. Scintigraphic changes in the salivary glands in patients with advanced stage of metabolic syndrome. Eur J Nucl Med Mol Imaging 2006, 33(Suppl.):S360.
58. Sen S., Duman R., Sanacora G. Serum BDNF, depression and antidepressant medications: meta-analyses and implication. Biol Psychiatry 2008, 64:527-532.
59. Jewett K.A., Krueger J.M. Humoral sleep regulation; interleukin-1 and tumor necrosis factor. Vitam Horm 2012, 89:241-257.
60. Dimitrijevic M., Stanojevic S. Neuropeptide Y: the story, the players, the outcomes. Nerve-Driven Immunity 2012, 227-255. Springer Verlag, Wien. M. Levite (Ed.).
61. Gonzalez-Gay M., Gonzalez-Juanatey C., Vazquez-Rodriguez T., Miranda-Filloy J., Llorca J. Insulin resistance in rheumatoid arthritis: the impact of the TNF-α therapy. Ann N Y Acad Sci 2010, 1193:153-159.
62. Simoncig-Netjasov A., Vujović S., Ivović M., Tancić-Gajić M., Drezgić M. Gaining weight and components of metabolic syndrome in the period of menopause. Srp Arh Celok Lek 2008, 136:505-513. (in Serbian).
63. Wiernsperger N., Nivoit P., De Aguiar L.G., Bouskela E. Microcirculation and the metabolic syndrome. Microcirculation 2007, 14:403-438.
64. Wallerius S., Rosmond R., Ljung T., Holm C., Björntorp P. Rise in morning saliva cortisol is associated with abdominal obesity in men: a preliminary report. J Endocrinol Invest 2003, 6:616-619.
65. Luther J.A., Birren S.J. P75 and TrKA signaling regulates sympathetic neuronal firing patterns via differential modulation of voltage-gated currents. J Neurosci 2009, 29:5411-5424.
66. Apfel S. Neurotrophic factors and diabetic peripheral neuropathy. Eur Neurol 1999, 41(Suppl. 1):27-34.
67. Chaldakov G.N., Tonchev A.B., Manni L., et al. Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia 2007, 50:431-438. Krabbe KS, Nielsen AR, Krogh-Madsen R, et al. Diabetologia 2007; 50: 1781-1782.
68. Licht C.M., Vreeburg S.A., Van Reedt Dortland A. Increased sympathetic and decreased parasympathetic activity rather than changes in hypothalamic-pituitary-adrenal axis activity is associated with metabolic abnormalities. J Clin Endocrinol Metab 2010, 95:2458-2466.
69. Panina E.B., Botvinnik V.S. The role of autonomic dysfunction in the pathogenesis of metabolic disorders in patients with metabolic alimentary obesity. Zh Nevropatol Psikhiatr im S S Korsakova 1992, 92(5-12):22-24. (in Russian).
70. Manneras L., Cajander S., Lönn M., Stener-Victorin E. Acupuncture and exercise restore adipose tissue expression sympathetic markers and improve ovarian morphology in rats with dihydrotestosterone-induced PCOS. Am J Physiol Regul Integr Comp Physiol 2009, 296:R1124-R1131.
71. Egan B.M. Insulin resistance and the sympathetic nervous system. Curr Hypertens Rep 2003, 5:247-254.
72. Rosas-Ballina M., Tracey K.J. Cholinergic control of inflammation. J Intern Med 2009, 265:663-679.
73. Das U.N. Vagus nerve stimulation as a strategy to prevent metabolic syndrome. Med Hypotheses 2011, 76:429-433.
74. Tyagi E., Agrawal R., Nath C., Shukla R. Inhibitory role of cholinergic system mediated via alpha 7 nicotinic acetylcholine receptor in LPS-induced neuroinflammation. Innate Immun 2010, 16:3-13.
75. Sloan R., McCreath H., Tracey K., Sidney S., Liu K., Seeman T. RR interval variability is inversely related to inflammatory markers: the CARDIA study. Mol Med 2007, 13:178-184.
76. Nakra N., Bhargava S., Dzuira J., Caprio S., Bazzy-Asaad A. Sleep-disordered breathing in children with metabolic syndrome: the role of leptin and sympathetic nervous system activity and the effect of continuous positive airway pressure. Pediatrics 2008, 122:e634-e642. 10.1542/peds.2008-0154.
77. Grassi G., Arenare F., Quarti-Trevano F., Seraralle G., Mancia G. Heart rate, sympathetic cardiovascular influences, and the metabolic syndrome. Prog Cardiovasc Dis 2009, 52:31-37.
78. Straznicky N.E., Lambert E.A., Nestel P.J., et al. Sympathetic neural adaptation to hypocaloric diet with or without exercise training in obese metabolic syndrome subjects. Diabetes 2010, 59:71-79.
79. Shaked I., Meerson A., Wolf Y., et al. Micro RNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetyl cholinesterase. Immunity 2009, 31:965-973.
80. Hristova M., Chaldakov G., Fiore M., Atanasova P., Aloe L. Serum acetylcholinesterase levels in metabolic syndrome. Nauka endokrinol 2010, 6:221-222. (in Bulgarian).
81. Inanaga K., Ichiki T., Miyazaki P., et al. Acetylcholinesterase inhibitors attenuate atherogenesis in apolipoprotein E-knockout mice. Atherosclerosis 2010, 213:52-58.
82. Langeray A., Launay J.M., Calleberst J., Surget A., Belzung C., Barone P.R. Peripheral and cerebral metabolic abnormalities of the tryptophan-kynurenine pathway in a murine model of major depression. Behav Brain Res 2010, 210:84-91.
83. Szczepanska-Sadowska E., Cudnoch-Jedrzejewska A., Ufnal M., Zera T. Brain and cardiovascular disease: common neurogenic background of cardiovascular, metabolic and inflammatory diseases. J Physiol Pharmacol 2010, 61:509-521.
84. Oxenkrug G.F. Metabolic syndrome, age-associated neuroendocrine disorder and dysregulation of tryptophan-kynurenine metabolism. Ann N Y Acad Sci 2010, 1199:1-14.
85. Rasmusson A., Schnurr P., Zukowska Z., Scioli E., Forman D. Adaptation to extreme stress: post-traumatic stress disorder neuropeptide Y and metabolic syndrome. Exp Biol Med (Maywood) 2010, 235:1150-1162.
86. Maury E., Ramsey K., Bass J. Circadian rhythms and metabolic syndrome: from experiment genetics to human disease. Circ Res 2010, 106:447-462.
87. Achike F.I., To N.H., Wang H., Kwan C.Y. Obesity, metabolic syndrome, adipocytes, and vascular function: a holistic viewpoint. Clin Exp Pharmacol Physiol 2011, 38:1-10.
88. Jones A., Kulozik P., Ostertag A., Herzig S. Common pathological processes and transcriptional pathways in Alzheimer's disease and type 2 diabetes. J Alzheimer's Dis 2009, 16:787-808.
89. Chaldakov G.N., Tonchev A.B., Aloe L. NGF and BDNF: from nerves to adipose tissue, from neurotrophines to metabokines. Riv Psichiatr 2009, 44:79-87.
90. Luther J.A., Birren S.J. Neurotrophins and target interactions in the development and regulation of sympathetic neuron electrical and synaptic properties. Auton Neurosci 2009, 151:46-80.
91. Ziegenhorn A.A., Schulte-Herbrüggen O., Danker-Hopfe H., et al. Serum neurotrophins - a study on the time course and influencing factors in a large old age sample. Neurobiol Aging 2007, 28:1436-1445.
92. Browne S.E., Lin L., Mattsson A., Georgievska B., Isacson O. Selective antibody-induced cholinergic cell and synapse loss produce sustained hippocampal and cortical hypometabolism with correlated cognitive deficits. Exp Neurol 2001, 170:36-47.
93. Kilari A., Mehendale S., Pisal H., Panchanadikar T., Kale A., Joshi S. Nerve growth factor, birth outcome and pre-eclampsia. Int J Dev Neurosci 2011, 29:71-75.
94. Chaldakov G. The metabotrophic NGF and BDNF: an emerging concept. Arch Ital Biol 2011, 149:257-263.
95. Hansen-Algenstaedt N., Algenstaedt P., Schaefer C., et al. Neural driven angiogenesis by overexpression of nerve growth factor. Histochem Cell Biol 2006, 125:637-649.
96. Sanchez-Patan F., Anchuelo R., Aller M., et al. Chronic prehepatic portal hypertension in the rat: is it a type of metabolic inflammatory syndrome. Lipids Health Dis 2008, 13(7):4. 10.1186/1476-511X-7-4.
97. Sharma H.S. Neurotrophic factors in combination: a possible new therapeutic strategy to influence pathophysiology of spinal cord injury and repair mechanisms. Curr Pharm Des 2007, 13:1841-1874.
98. Zolads J.A., Pilc A. The effect of physical activity on the brain-derived neurotrophic factor: from animal to human studies. J Physiol Pharmacol 2010, 61:533-541.
99. Bus B.A.A., Tendolkar I., Franke B., et al. Serum brain-derived neurotrophic factor: determinants and relationship with depressive symptoms in a community population of middle-aged and elderly people. World J Biol Psychiatry 2012, 13:39-47.
100. Bus B.A.A., Molendijk M.L., Penninx B.J.W.H., et al. Determinants of serum brain-derived neurotrophic factor. Psychoneuroendocrinology 2011, 36:228-239.
101. Heber D. An integrative view of obesity. Am J Clin Nutr 2010, 92:280S-283S.
102. Galic S., Oakhill J., Steinberg G. Adipose tissue as an endocrine organ. Mol Cell Endocrinol 2010, 316:129-139.
103. Conde J., Scotece M., Gomez R., Gomez-Reino J., Lago F., Gualillo O. At the crossroad between immunity and metabolism: focus - leptin. Expert Rev Clin Immunol 2010, 6:801-808.
104. Kadoglou N., Tsanikidis H., Kapelouzou A., et al. Effect of rosiglitazone and metformin treatment on apelin, vistatin and ghrelin levels in patients with type 2 diabetes mellitus. Metab Clin Exp 2010, 59:373-379.
105. Guo X., Roberts M.R., Becker S.M., et al. Leptin signaling in intestinal epithelium mediates resistance to enteric infection by Entamoeba histolytica. Mucosal Immunol 2011, 4:294-303.
106. Hilenbrand A., Knippschild V., Weiss M., et al. Sepsis induced changes of adipokines and cytokines-septic patients compared to morbidly obese patients. BMC Surg 2010, 9(10):26. 10.1186/1471-2482-10-26.
107. Koch C., Augustine R., Steger J., et al. Leptin rapidly improves glucose homeostasis in obese mice increasing hypothalamic insulin sensitivity. J Neurosci 2010, 30:16180-16187.
108. Kowalska I., Straczkowski M., Nikolajuk A., et al. Insulin resistance, serum adiponectin and proinflammatory markers in young subjects with the metabolic syndrome. Metabolism 2008, 57:1539-1544.
109. Maury E., Brichard S.M. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 2010, 314:1-16.
110. Esteghamati A., Khalilzadeh O., Anvari M., Rashidi A., Mokhtari M., Nakhjavani M. Association of serum leptin levels with homeostasis models assessment-estimated insulin resistance and metabolic syndrome: the key role of central obesity. Metab Syndr Relat Disord 2009, 7:4452-4457.
111. Camera A., Hopps E., Caimi G. Metabolic syndrome: from insulin resistance to adipose tissue dysfunction. Minerva Med 2008, 99:307-321.
112. Gade W., Schmit J., Collins M., Gade J. Beyond obesity: the diagnosis and pathophysiology of metabolic syndrome. Clin Lab Sci 2010, 23:51-61. quiz 62-65.
113. Skrypnyk N.V. Correlation between adipocytokines with iodine deficiency criteria in patients with metabolic syndrome and type 2 diabetes mellitus in Carpathians region. Lik Sprava 2010, 12:70-77. (in Ukrainian).
114. Rhee S.D., Sug Y.Y., Lee Y.S., et al. Obesity of TallyHO/JngJ mouse is due to increased food with early development of leptin resistance. Exp Clin Endocrinol Diabetes 2011, 119:243-251.
115. Beltowski J. Leptin and atherosclerosis. Atherosclerosis 2006, 189:47-60.
116. Beltowski J., Wojcicka G., Jamroz-Wisniewska A., Wojtak A. Chronic hyperleptinemia induces resistance to acute NO-mimetic effects of leptin. Peptides 2010, 31:155-163.
117. Paulos S., Hausman D., Hausman G. The development and endocrine functions of adipose tissue. Mol Cell Endocrinol 2010, 323:20-34.
118. Fernandez-Riejos P., Najib S., Santos-Alvarez J., et al. Role of leptin in the activation of immune cells. Mediators Inflamm 2010, 2010:568343. 10.1155/2010/568343.
119. Hristova M., Aloe L., Ghenev P.I., Fiore M., Chaldakov G.N. Leptin and mast cells: a novel adipoimmune link. Turk J Med Sci 2001, 31:581-583.
120. Cao L., Liu X., Lin E.J., et al. Environmental and genetic activation of a brain-adipocyte BDNF/leptin axis causes cancer remission and inhibition. Cell 2010, 142:52-64.
121. Hamnvik O.P., Liu X., Petrou M., et al. Soluble leptin receptor and leptin are associated with base adiposity and metabolic risk factors, and predict adiposity metabolic syndrome, and glucose levels at 2-year follow-up: Cyprus Metabolism Prospective Cohort Study. Metabolism 2011, 60:987-993.
122. Nomura K., Eto M., Kojima T., et al. Visceral fat accumulation and metabolic risk factor cluster in older adults. J Am Geriatr Soc 2010, 58:1658-1663.
123. Balbo M., Leproulet R., Van Cauter E. Impact of sleep and its disturbances on hypothalamo-pituitary-adrenal axis activity. Int J Endocrinol 2010, 759234. doi: 10.1155/2010/759234.
124. Nieuwenhuizen A.G., Rutters F. The hypothalamic-pituitary-adrenal-axis in the regulation of energy balance. Physiol Behav 2008, 94:169-177.
125. Guijarro A., Laviano A., Meguid M. Hypothalamic integration of immune function and metabolism. Prog Brain Res 2006, 153:367-405.
126. Matrisciano F., Modafferri A., Togna G., et al. Repeated anabolic androgenic steroid treatment causes antidepressant-reversible alterations of the hypothalamic-pituitary-adrenal axis, BDNF levels, and behavior. Neuropharmacology 2010, 58:1078-1084.
127. Fuite J., Vernon S., Broderick G. Neuroendocrine and immune network re-modeling in chronic fatique syndrome: an exploratory analysis. Genomics 2008, 92:393-399.
128. Simoncig-Netjasov A., Vujovic S., Ivovic M., Tancic-Gajic M., Drezgic M. Influence of duration of menopause, anthropometric and hormonal parameters on metabolic syndrome. Med pregl 2010, 63:33-39. (in Serbian).
129. De Pergola G., Giorgino F., Benigno R., Guida P., Giorgino R. Independent influence of insulin, catecholamines, and thyroid hormones on metabolic syndrome. Obesity 2008, 16:2405-2411.
130. Sen Y., Aygun D., Yilmaz E., Ayar A. Children and adolescents with obesity and the metabolic syndrome have high circulating cortisol levels. Neuro Endocrinol Lett 2008, 29:141-145.
131. Anagnostis P., Athyros V., Tziomalos K., Karagiannis A., Mikhailidis D. The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab 2009, 94:2692-2701.
132. Vogelzangs N., Beekman A., Dik M., et al. Late-life depression, cortisol and the metabolic syndrome. Am J Geriatr Psychiatry 2009, 17:716-721.
133. Phillips A.C., Carroll D., Gale C.R., Lord J.M., Aret W., Batty G.D., et al. Cortisol, DHEAS, their ratio and the metabolic syndrome: evidence from the Vietnam Experience Study. Eur J Endocrinol 2010, 162:919-923.
134. Friedman M., Miranda-Massari J.R., Gonzales M.J. Supraphysiological cyclic dosing of sustained release T3 in order to reset low basal body temperature. P R Health Sci J 2006, 25:23-29.
135. Van Zaane B., Reuwer A., Büller H., Kastelein J., Gerdes V., Twickler M. Hormones and cardiovascular disease: a shift in paradigm clinical consequences?. Semin Thromb Hemost 2009, 35:478-487.
136. Redig A.J., Munshi H.G. Metabolic syndrome after hormone-modifying therapy: risks associated with antineoplastic therapy. Oncology (Williston Park) 2010, 24:839-844.
137. Zitzmann M. Testosterone deficiency, insulin resistance and the metabolic syndrome. Nat Rev Endocrinol 2009, 5:673-681.
138. Stanworth R.D., Jones T.H. Testosterone in obesity, metabolic syndrome and type 2 diabetes. Front Horm Res 2009, 37:74-90.
139. Traish A.M., Saad F., Feeley R.J., Guay A. The dark side of testosterone deficiency: III. Cardiovascular disease. J Androl 2009, 30:477-494.
140. Roos A., Bakker S., Links T., Gans R., Wolffenbuttel B. Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects. J Clin Endocrinol Metab 2007, 92:491-496.
141. Popovic V., Pekic S., Pavlovic D., et al. Hypopituitarism as a consequence of traumatic brain injury (TBI) and its possible relation with cognitive disabilities and mental distress. J Endocrinol Invest 2004, 27:1048-1054.
142. Naert G., Ixart G., Maurice T., Tapia-Arancibia L., Givalois L. Brain-derived neurotrophic factor and hypothalamic-pituitary-adrenal axis adaptation processes in a depressive-like state induced by chronic restraint stress. Mol Cell Neurosci 2011, 46:55-66.
143. Cordeira J.W., Frank L., Sena-Esteves M., Pothos E.N., Rios M. Brain-derived neurotrophic factor regulates hedonic feeding by acting on the mesolimbic dopamine system. J Neurosci 2010, 30:2533-2541.
144. Toriya M., Maekawa F., Maejima Y., et al. Long-term infusion of brain-derived neurotrophic factor reduces food intake and body weight via a corticotrophin-releasing hormone pathway in the paraventricular nucleus of the hypothalamus. J Neuroendocrinol 2010, 22:987-995.
145. Wang C., Bomberg E., Billington C.J., Levine A.S., Kotz C.M. Brain-derived neurotrophic factor (BDNF) in the hypothalamic ventromedial nucleus increases energy expenditure. Brain Res 2010, 1336:66-77.
146. Burns B., Schmidt K., Williams S.R., Kim S., Girirajan S., Elsea S.H. Rai1 haploinsufficiency causes reduced BDNF expression resulting in hyperphagia, obesity and altered fat distribution in mice and humans with no evidence of metabolic syndrome. Hum Mol Genet 2010, 19:4026-4042.
147. Tozuka Y., Kumon M., Wada E., Onodera M., Mochizuki H., Wada K. Maternal obesity impairs hippocampal BDNF production and spatial learning performance in young mouse offspring. Neurochem Int 2010, 57:235-247.
148. Badowska-Szalewska E., Spodnik E., Ludkiewicz B., Klejbor I., Moryś J. Nerve growth factor (NGF) immunoreactive neurons in the juvenile rat hippocampus: response to acute and long-term high-light open-field (HL-OF) or forced swim (FS) stress stimulation. Neuroscience 2011, 199:491-500.
149. Badowska-Szalewska E., Klejbor I., Cecot T., Spodnik J.H., Moryś J. Changes in NGF/c-Fos double staining in the structures of the limbic system in juvenile and aged rats exposed to forced swim test. Acta Neurobiol Exp 2009, 69:1-11.
150. Elzinga B.M., Molendijk M.L., Oude Voshaar R.C., et al. The impact of childhood abuse and recent stress on serum brain-derived neurotrophic factor and the moderating role of BDNF Val66Met. Psychopharmacology 2011, 214:319-328. (Berlin).
151. Raap U., Braunskahl G.J. The role of neurotrophins in the pathophysiology of allergic rhinitis. Curr Opin Allergy Clin Immunol 2010, 10:8-13.
152. Scuri M., Samsell L., Piedimonte G. The role of neurotrophins in inflammation and allergy. Inflamm Allergy Drug Targets 2010, 9:173-180.
153. Yuan H., Zhu X., Zhou S., et al. Role of mast cell activation in inducing microglial cells to release neurotrophin. J Neurosci Res 2010, 88:1348-1354.
154. Luczynski W., Bossowski A., Glowinska-Olszewska B., Kos J., Stasiak-Barmuta A. The role of T-regulatory cells in the pathogenesis of immunological disturbances accompanying obesity and atherosclerosis. Postery Hig Med Dosw (Online) 2010, 64:156-160. (Polish).
155. Dines K.C., Powell H.C. Mast cell interactions with the nervous system: relationship to mechanisms of disease. J Neuropathol Exp Neurol 1997, 56:627-640.
156. Chakraborty S., Zawieja S., Wang W., Zawieja D.C., Muthuchamy M. Lymphatic system: a vital link between metabolic syndrome and inflammation. Ann N Y Acad Sci 2010, 1207(Suppl. 1):E94-E102.
157. Magnussen C.G., Koskiuen J., Chen W., et al. Pediatric metabolic syndrome predicts adulthood metabolic syndrome, subclinical atherosclerosis, and type 2 diabetes mellitus but is no better than body mass index alone: the bogalusa heart study and the cardiovascular risk in young finns study. Circulation 2010, 122:1604-1611.
158. Gorelick P.B. Role of inflammation in cognitive impairment: results of observational epidemiological studies and clinical trials. Ann N Y Acad Sci 2010, 1207:155-162.
159. Chaldakov G.N., Tonchev A.B., Fiore M., et al. Implications for the future of obesity management. Frontiers in nutritional science, no 4. peptides in energy balance & obesity 2009, 369-389. CAB International, Oxfordshire. G. Frühbeck (Ed.).
160. Andel M., Polak J., Kramp P., Dlouhy P., Stich V. Chronic mild inflammation links obesity, metabolic syndrome, atherosclerosis and diabetes. Vnitr Lek 2006, 55:659-665. (Czech).
161. Sangun Ö., Dündar B., Köşker M., Pirgon Ö., Dündar N. Prevalence of metabolic syndrome in obese children and adolescents using tree different criteria and evaluation of risk factors. J Clin Res Ped Endocrinol 2011, 3:70-76.
162. Ford E., Li C., Zhao G. Prevalence and correlates of metabolic syndrome based on harmonious definition among adults in the US. J Diabetes 2010, 2:180-193.
163. Zuo H., Shi Z., Hu X., Wu M., Guo Z., Hussain A. Prevalence of metabolic syndrome and factors associated with its components in Chinese adults. Metabolism 2009, 58:1102-1108.
164. Thomas G., Phillips A., Carroll D., Gale C., Batty G. The metabolic syndrome adds utility to the prediction of mortality over its components. The Vietnam Experience Study. Atherosclerosis 2010, 210:256-261.
165. Chaudhary K., Buddineni J.P., Nistala R., Whaley-Connell A. Resistant hypertension in the high-risk metabolic patient. Curr Diab Rep 2011, 11:41-46.
166. Aspirin therapy in diabetes American diabetes association position statement. Diabetes Care 2004, 27:S72-S73.
167. Thompson M., Trayhurn P. Effect of salicylate on the expression of adipokines and glucose transporters in human adipocytes is modulated by hypoxia. Horm Metab Res 2009, 41:649-652.
168. Pomponi M., Di Gioia A., Bria P., Pomponi M. Fatty aspirin: a new perspective in the prevention of dementia of Alzheimer's type?. Curr Alzheimer Res 2008, 5:422-431.
169. Suwa M., Yamamoto K., Nakano H., Sasaki H., Radak Z., Kumagai S. Brain-derived neurotrophic factor treatment increases the skeletal muscle glucose transporter 4 protein expression in mice. Physiol Res 2010, 59:619-623.
170. Dutheil F., Lesourd B., Courteix D., Chapier R., Doré E., Lac G. Blood lipids and adipokines concentrations during a 6-month nutritional and physical activity intervention for metabolic syndrome treatment. Lipids Health Dis 2010, 9:148. 10.1186/1476-511X-9-148.
171. Wood I., de Heredia F., Wang B., Trayhurn P. Cellular hypoxia and adipose tissue dysfunction in obesity. Proc Nutr Soc 2009, 68:370-377.
172. Maury E., Noel L., Detry R., Brichard S.M. In vitro hyperresponsiveness to tumor necrosis factor-alpha contributes to adipokine dysregulation in omental adipocytes of obese subjects. J Clin Endocrinol Metab 2009, 4:1393-1400.
173. Chaldakov G.N., Fiore M., Tonchev A.B., Hristova M.G., Nikolova V., Aloe L. Tissue with high intelligence quotient: adipose-derived stem cells in neural regeneration. Neural Regen Res 2009, 4:1116-1120.
174. Chaldakov G.N., Fiore M., Tonchev A.B., Hristova M.G., Rancic G., Aloe L. The adipose tissue as a third brain. Obes Metab (Milan) 2009, 5:94-96.
175. Krueger J.M., Majde J.A., Rector D.M. Cytokines in immune function and sleep regulation. Handb Clin Neurol 2011, 98:229-240.
176. Sarac S., Sarac F., Tütüncüoglu P. Effects of telmisartan and valsartan on insulin resistance, visfatin and adiponectin levels in hypertensive patients with metabolic syndrome. Acta Endocrinol (Bucharest) 2008, 4:23-32.
177. Iacobellis G., di Gioia C., Cotesta D., et al. Epicardial adipose tissue adiponectin expression is related to intracoronary adiponectin levels. Horm Metab Res 2009, 41:227-231.
178. Arouma O.I., Nayashi Y., Marotta F., Mantello P., Rachmilewitz E., Montagnier L. Applications and bioefficacy of the functional food supplement fermented papaya preparation. Toxicology 2010, 278:6-16.
179. Zoladz J.A., Pilc A., Majerczak J., Grandys M., Zapart-Bukowska J., Duda K. Endurance training increases plasma brain-derived neurotrophic factor concentration in young healthy men. J Physiol Pharmacol 2008, 59(Suppl. 7):119-132.
180. Molnár I. A tartós stressz hatása a szervezet védekezoké pességére, a krónikus gyulladások és a daganatok kialakulására. Lege Artis Med 2010, 20:31-37.
181. Soliman K.M., Mohamed A.M., Metwally N.S. Attenuation of some metabolic deteriorations induced by diabetes mellitus using carnosine. J Appl Sci 2007, 7:2252-2260.
182. Filuś J., Rybakowski J. Serum BDNF levels and intensity of depressive symptoms. Neuropsychiatry Neuropsychol 2010, 5:155-162.
183. Szanton S.L., Gilla J.M., Thorpe R.J. The society-to-cells model of resilience in older adults. Annu Rev Gerontol Geriatr 2010, 30:5-34.
184. Molendijk M.L., Bus B.A., Spinhoven P., et al. Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. Mol Psychiatry 2011, 16:1088-1095.
185. Badowska-Szalewska E., Spodnik E., Klejbor I., Ludkiewicz B., Moryś J. Do two models of acute and chronic stress stimulation influence the amount of nerve growth factor (NGF) and its receptor TrkA in the hippocampal neurons of middle aged rats?. Brain Res 2011, 1384:97-109.
186. Classen J.B. Review of evidence that epidemics of type 1 diabetes and type 2 diabetes/metabolic syndrome are polar opposite responses to iatrogenic inflammation. Curr Diabetes Rev 2012, 8:413-418.